Immune Cell Assay CRO Services
Outsource immune cell assays to a specialist preclinical CRO
BioMedha is a preclinical immunology CRO providing immune cell assay services to US biotechnology and pharmaceutical companies, including teams based in Boston and across the US.
We support early drug discovery with human-relevant, decision-ready in vitro immunology data, delivered by a small, flexible scientific team.
- Human immune cell & PBMC-based assays
- Decision-ready in vitro immunology data
- Flexible, scientist-led CRO support
Start Your Project
Immune Cell Assay Services for Early Drug Discovery
BioMedha designs and delivers custom immune cell assays aligned to your biology, target, and program goals. We support discovery teams looking to outsource immune cell testing to a CRO with the expertise to generate meaningful, actionable data.
- T cell functional and activation assays
- B cell assays
- Monocyte and macrophage assays
- Neutrophil assays
- Dendritic cell assays
Assays are used to assess immune activation, inhibition, differentiation, cytokine release, and functional response, supporting immunology, inflammation, and immuno-oncology programs.
Whole Blood and Translational Immunology Assays
Where physiological relevance is critical, we provide whole blood and donor-derived immune assays, including:
Cytokine and cytokine secretion assays
Cytokine and cytokine secretion assays
Innate immune function assays
Innate immune function assays
Immunogenicity and immune safety assessment
Immunogenicity and immune safety assessment
Using human donor material helps reduce translational risk and provides insight that is more predictive of clinical response.
Integrated Immunology and Cell Biology Capabilities
Immune cell assays at BioMedha are supported by complementary in vitro platforms, including:
Flow cytometry for immune phenotyping and functional analysis
Flow cytometry for immune phenotyping and functional analysis
Cell imaging for phenotypic and mechanistic insight
Cell imaging for phenotypic and mechanistic insight
Target expression and biomarker analysis
Target expression and biomarker analysis
This integrated capability allows us to design studies around the full biological context of immune responses, not isolated readouts.
Flexible Immunology CRO with Direct Scientist Access
BioMedha is a specialist immunology CRO built to support agile drug discovery teams. Our small, experienced scientific team allows us to move quickly, adapt to evolving programmes, and stay closely aligned with client objectives
Small and Flexible by Design
Assay development built around your programme
Reliable Turnaround and High-Quality Data
Decision-ready results, delivered on time
Direct Access to Bench Scientists
Clear, open scientific communication
Why US Biotech Teams Choose BioMedha
- Industry-experienced in vitro immunology scientists
- Bespoke assay development aligned to your biology and timeline
- Strong focus on human primary cells and translational relevance
- Flexible CRO support — single assays or integrated programs
- Direct communication with scientists running your studies
BioMedha developed a robust cytokine storm assay using PBMCs isolated from healthy donor whole blood to assess early immunogenicity risk.
Case Study Highlight
Cytokine Storm Assay for Immunogenicity Risk Assessment
Predictive in-vitro immunogenicity assessment using human PBMCs
Who We Typically Support
US biotech companies advancing early discovery programmes
Pharma teams requiring specialist immunology expertise
Venture-backed startups needing flexible CRO support
BioMedha is a small, highly experienced preclinical CRO based in Nottingham, UK, working closely with US biotechnology and pharmaceutical companies, including teams in Boston and the wider US biotech hub.
Our size is intentional – it allows us to stay flexible, responsive and scientifically hands-on, while delivering to the standards expected by US discovery teams.